News
7d
Clinical Trials Arena on MSNRoche and Genentech’s Lunsumio-Polivy shows promise in Phase III trialRoche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...
Genentech is letting go of 143 employees who are based out of the company's headquarters in South San Francisco. | Genentech is letting go of 143 employees who are based out of the company's ...
Genentech is planning cuts on the Peninsula.
Genentech will close its cancer immunology research department, and unit head and renowned cell biologist Ira Mellman, who has been with the company for 17 years, will depart in the coming months.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the Phase III STARGLO study met its primary endpoint of overall s.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein ...
SOUTH SAN FRANCISCO, Calif., January 28, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the overall survival (OS) analysis ...
Genentech has been developing medicines to redefine treatment in oncology for more than 35 years, and today, realizing the full potential of cancer immunotherapy is a major area of focus.
Genentech will withdraw Gavreto from use in the United States for treating a type of thyroid cancer as it was not feasible for the Roche unit to pursue the drug for full approval, its partner ...
Genentech CEO Alexander Hardy, in an interview with STAT, explained that in the world that existed prior to the Inflation Reduction Act’s passage last year, ...
PIX Now Afternoon Edition 8-8-2023 14:42. SOUTH SAN FRANCISCO – Biotech firm Genentech will pay more than $150,000 in fines to settle claims of alleged hazardous waste violations at its facility ...
Genentech, where Stanford President Marc Tessier-Lavigne once served as chief scientific officer, confirmed on Thursday that there were concerns about Alzheimer’s research Tessier-Lavigne co ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results